Log In
Friday 21st October 2016

Charity invites industry to buy results

29th May 2008

Cancer Research UK has unveiled plans for major collaborations with pharmaceutical companies to take forward research into the disease.


The charity’s commercial arm, Cancer Research Technology (CRT), has announced that it is putting together “crack teams? of up to five leaders in their highly specialised fields to work together to bring on an early stage of cancer research.

In launching the initiative CRT’s senior business manager Simon Youlton said the projects are time limited to two years, over which period Cancer Research UK will spend £500,000 funding each team’s research.

Individual pharma companies are now being invited to buy into the first of the projects with a view to taking full ownership of the resulting knowledge.

Mr Youlton said the target areas for research had been specifically chosen because they had reached the stage of maturity in pure research to the point when it can be moved into drug discovery.

CRT says that it has been able to bring together a “novel but synergistic combination of talents? and a collaboration of scientists in a way that was difficult for pharma companies to achieve.

The first team, headed by Cancer Research UK scientist and professor of molecular oncology at Glasgow University, Nicol Keith, will look at cellular senescence.

Professor Keith stressed the business angle of CRT’s approach and added: “This is not blue-sky research this is about making ideas work in a very practical way.?

Two further projects for 2009 and 2010 looking at cancer stem cells and the histone code are planned.

Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Mayden - Innovative cloud-based applications for healthcare
© Mayden Foundation 2016